IRIS
TOFFOLETTI, Eleonora
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.020
AS - Asia 1.223
EU - Europa 968
SA - Sud America 187
AF - Africa 27
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.432
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.979
SG - Singapore 548
CN - Cina 293
UA - Ucraina 196
DE - Germania 145
BR - Brasile 138
IT - Italia 124
HK - Hong Kong 118
FI - Finlandia 100
VN - Vietnam 86
RU - Federazione Russa 78
SE - Svezia 77
FR - Francia 73
GB - Regno Unito 50
IN - India 49
TR - Turchia 41
IE - Irlanda 35
CA - Canada 21
AR - Argentina 19
CO - Colombia 15
BE - Belgio 14
BD - Bangladesh 13
KR - Corea 13
MX - Messico 12
PL - Polonia 12
CZ - Repubblica Ceca 9
ES - Italia 9
AT - Austria 8
JP - Giappone 8
NL - Olanda 8
IQ - Iraq 7
ZA - Sudafrica 7
EG - Egitto 6
SA - Arabia Saudita 6
ID - Indonesia 5
KZ - Kazakistan 5
RO - Romania 5
AU - Australia 4
CH - Svizzera 4
LT - Lituania 4
MA - Marocco 4
MY - Malesia 4
PK - Pakistan 4
UZ - Uzbekistan 4
BG - Bulgaria 3
BO - Bolivia 3
EU - Europa 3
PE - Perù 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
BY - Bielorussia 2
CL - Cile 2
EC - Ecuador 2
ET - Etiopia 2
HN - Honduras 2
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
JM - Giamaica 2
JO - Giordania 2
KE - Kenya 2
KG - Kirghizistan 2
NP - Nepal 2
OM - Oman 2
PY - Paraguay 2
RS - Serbia 2
TG - Togo 2
UY - Uruguay 2
AZ - Azerbaigian 1
BH - Bahrain 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GE - Georgia 1
GL - Groenlandia 1
KN - Saint Kitts e Nevis 1
LB - Libano 1
LI - Liechtenstein 1
LU - Lussemburgo 1
MU - Mauritius 1
NE - Niger 1
PH - Filippine 1
PS - Palestinian Territory 1
PT - Portogallo 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
VE - Venezuela 1
ZM - Zambia 1
Totale 5.432
Salva come PNG Salva come JPEG
Città #
Woodbridge 298
Ann Arbor 284
Ashburn 272
Singapore 258
Chandler 251
Fairfield 238
Houston 177
Beijing 176
Jacksonville 130
Hong Kong 117
Seattle 109
Wilmington 89
Dearborn 86
San Jose 83
Cambridge 66
Udine 53
Boardman 47
Los Angeles 42
Dallas 38
Lauterbourg 38
Munich 37
Princeton 36
Dublin 35
Izmir 35
New York 33
Trieste 25
Helsinki 24
Ho Chi Minh City 24
Council Bluffs 20
Turku 20
Buffalo 19
Mumbai 19
Hefei 18
San Diego 17
São Paulo 17
Hanoi 15
Orem 15
Brussels 14
Dong Ket 14
Redondo Beach 13
Bogotá 11
Des Moines 11
Seoul 11
Warsaw 11
Ogden 10
Frankfurt am Main 9
Phoenix 9
Atlanta 8
Chennai 8
Montreal 8
Nuremberg 8
Redmond 8
Tokyo 8
Chicago 7
Denver 7
The Dalles 7
Boston 6
Düsseldorf 6
Kunming 6
London 6
Pittsburgh 6
Stockholm 6
Vienna 6
Amsterdam 5
Cairo 5
Da Nang 5
Grafing 5
Manchester 5
Milan 5
Norwalk 5
Ottawa 5
Poplar 5
Prague 5
Querétaro 5
Rio de Janeiro 5
Toronto 5
Brooklyn 4
Haiphong 4
Johannesburg 4
Leicester 4
Madrid 4
Nanjing 4
Santa Clara 4
Tashkent 4
Brasília 3
Caxias do Sul 3
Contagem 3
Guangzhou 3
Hải Dương 3
Kuala Lumpur 3
La Paz 3
Lahore 3
Maceió 3
Mexico City 3
Ningbo 3
Raleigh 3
Riyadh 3
San Francisco 3
Secaucus 3
Shanghai 3
Totale 3.630
Salva come PNG Salva come JPEG
Nome #
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 222
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 197
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 196
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 195
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 189
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 178
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 177
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 177
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 172
Clonality and phenotype in spleens from patients with primary immune thrombocytopenia. 171
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 167
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 164
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 161
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 157
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 149
Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor 149
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 147
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 145
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 138
KIR POLYMORPHISM IN REDUCED INTENSITY HLA-ID SIBLING STEM CELL TRANSPLANTATION: IMPACT ON CLINICAL OUTCOME 138
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 135
Targeting kinase-activating genetic lesions to improve therapy of pediatric acute lymphoblastic leukemia 132
The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. 130
No evidence for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy” 122
Fludarabine-based induction therapy does not overcome the negative effect of bcrp (ABCG2) overexpression on remission duration in adult de novo acute myeloid leukemia patients 117
null 111
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response 107
WT1 – Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant 105
Clinical presentation, outcome and risk factors of late-onset non-infectious pulmonary complication after allogeneic transplantation 104
MONITORING OF MINIMAL RESIDUAL DISEASE BY QUANTITATIVE WT1 GENE EXPRESSION AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC SCT IN ACUTE MYELOID LEUKEMIA 101
CONCOMITANT OVEREXPRESSION OF BCRP AND FLT3-ITD MUTATION ARE ASSOCIATED WITH POOR PROGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS 99
MULTICENTER PROSPECTIVE CLINICAL TRIAL WITH LOW DOSE GEMTUZUMAB-OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN (GO-FLAI) AS INDUCTION THERAPY OF CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS YOUNGER THAN 65 YEARS 98
Longitudinal follow up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogenic bone marrow transplant 97
OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANT FOR REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA 97
QUANTITATIVE ANALYSIS OF MN1 GENE EXPRESSION FOR EVALUATION OF MINIMAL RESIDUAL DISEASE IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA PATIENTS 90
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduce intensity conditioning allogenic stem cell transplantation in acute myeloid leukaemia 88
Expression and modulation of S100A4 protein by human mast cells 82
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the “GRUPPO TRIVENETO LMC” 78
A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias 77
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study 57
New Combination Regimens vs. Fludarabine, Cytarabine, and Idarubicin in the Treatment of Intermediate- or Low-Risk Nucleophosmin-1-Mutated Acute Myeloid Leukemia: A Retrospective Analysis from 7 Italian Centers 46
Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia 35
Novel e4a2 BCR∷ABL1 transcript with insertion of CSE1L exons 9 and 10 in a CML patient: a case report 34
High JAK2V617F allele burden in low-risk PV: an additional recommendation to start “early” cytoreduction? Results from a multicentric study 26
ABCG2 AND HAVCR2 SNPS ARE ASSOCIATED WITH LONG-TERM TFR MAINTENANCE IN CML PATIENTS 11
NEXT GENERATION SEQUENCING IN TRIPLE NEGATIVE ESSENTIAL THROMBOCYTHEMIA: IMPACT OF ADDITIONAL MUTATIONS IN RISK ASSESSMENT 7
PROGNOSTIC IMPACT OF EXTENDED MOLECULAR CHARACTERIZATION BY NEXT-GENERATION SEQUENCING IN INTERMEDIATE RISK ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE INDUCTION CHEMIOTERAPY: A RETROSPECTIVE MONOCENTRIC STUDY 3
Totale 5.578
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.111
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.111
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021140 0 0 0 0 0 0 0 0 0 21 87 32
2021/2022368 18 35 16 21 22 9 22 10 10 54 96 55
2022/2023531 52 48 5 80 48 116 3 61 71 11 24 12
2023/2024143 19 16 5 4 20 18 2 8 14 8 7 22
2024/2025797 23 55 17 22 63 25 65 49 93 45 141 199
2025/20261.455 172 169 115 118 280 136 165 40 123 137 0 0
Totale 5.578